Topical steroid withdrawal community feels sting of NIH turmoil
On May 23, 2023, Kelly Barta made her way to the National Institutes of Health (NIH) to seek answers about her condition. Barta had been dealing with eczema since childhood, which had led to her being prescribed topical steroids. However, after years of using these steroids, she found herself in a worsening state. The pharmacist’s concern about the potency of the steroids she had been using for a decade triggered a realization in Barta – she might be suffering from topical steroid withdrawal (TSW).
The symptoms of TSW were debilitating for Barta. She experienced intense itching, oozing skin, and unbearable discomfort that affected almost her entire body. The relentless itch was described as a panic attack, leading to sleepless nights and constant agony. As she delved deeper into her condition, Barta discovered the term TSW and found that it resonated with her experiences.
The journey to uncover the biology of TSW was fraught with challenges. Many doctors were skeptical of the condition, attributing it to a resurgence of eczema rather than a distinct disorder. This skepticism fueled the advocacy efforts of TSW patients like Barta, who were determined to bring attention to their plight. When allergist-immunologist Ian Myles at the NIH took an interest in TSW, it marked a significant turning point. Myles initiated a study involving patients with TSW, eczema, and healthy volunteers to investigate potential differences at a biological level.
The study revealed intriguing findings, showing elevated levels of vitamin B3 and reduced levels of tryptophan in TSW patients compared to those with eczema. This pointed towards a potential mitochondrial involvement in TSW, offering a new perspective on the condition. Myles went a step further by suggesting metformin and berberine as possible interventions based on the study results.
However, the path to further research on TSW faced obstacles. Budget constraints, staff layoffs, and shifting priorities within the NIH due to administrative changes hindered Myles’ plans for a larger berberine trial. Despite the setbacks, the pursuit of understanding TSW continued, with researchers in the UK also exploring biological patterns in TSW patients.
The unfolding saga of TSW underscored the complexities of medical research and patient advocacy. While some questioned the validity of the findings, others emphasized the need for continued investigation and validation. The narrative of TSW intertwined with the history of corticosteroids, highlighting the delicate balance between therapeutic benefits and potential side effects of these drugs.
As the quest for unraveling the mysteries of TSW persisted, the importance of scientific inquiry and collaboration remained paramount. The challenges faced in studying TSW reflected broader shifts in research priorities and resource allocation within the scientific community. Despite the hurdles, the dedication of individuals like Kelly Barta and Ian Myles exemplified the resilience and determination required to advance understanding in the field of dermatology.
